AI-generated · cited to primary sources · not investment advice
Gland Pharma (543245) Aug 2025 Filing Analysis
Does management do what it says?
The launch has shifted slightly from the September quarter to the current quarter (Q3 FY26), with the goal date set for November 2025. (3 revised, 1 met across 4 tracked commitments)
“The other big thing in the US will be Dalbavancin launch. That will be the September quarter. That's on track again in terms of the approval and launch.”
See the full cited Management analysis of Gland Pharma
How durable is the business?
The company continues to strengthen its regulatory moat with 9 new product approvals in the US and 1,761 global registrations during the quarter. (5 expanding)
“In-house R&D continues to be a strong driver with One ANDA filed and nine approved alongside 1,761 global registrations in the quarter.”
The base business saw improved profitability margins, with gross margins rising to 59% from 53% in the previous year's quarter, primarily due to favorable raw material costs. (1 expanding)
“Excluding Cenexi, our base business gross margin stood at 59% in Q1 FY '26, up from 53% in the same quarter of previous year.”
The US market remains the largest revenue contributor at 49%, though it faced a slight 2% decline in revenue due to the timing of Enoxaparin supplies, which was partially offset by nine new product launches. (2 contracting, 3 expanding)
“The U.S. reported INR 7,443 million in revenues, contributing to 49% of our business.”
See the full cited Business Model analysis of Gland Pharma
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.